Background {#Sec1}
==========

Dizziness occurs frequently in older people. The prevalence of dizziness in older people ranges from 8 % in the primary care population to 30 % in the community, and increases with age \[[@CR1]--[@CR7]\]. For doctors, dizziness is a challenging entity to deal with: patients use the term dizziness for a variety of sensations, and the complaint dizziness may accompany harmless but also very serious conditions. Dizziness is a fuzzy concept that can refer to several sensations, including a giddy or rotational sensation, a loss of balance, a faint feeling, light-headedness, instability or unsteadiness, a tendency to fall, or a feeling of everything turning black \[[@CR8]\]. Dizziness in older people can have serious consequences. Dros et al. reported that more than 60 % of older dizzy people in primary care experience moderate or severe impact on daily living due to dizziness \[[@CR9]\]. Furthermore, dizziness is associated with worsening of depressive symptoms, self-rated health, and social activities \[[@CR10]\]. Older people who experience dizziness also have an increased fall risk \[[@CR10]\], leading to injury and high healthcare costs \[[@CR11]\]. Hartholt et al. showed that 3 % of all Dutch people aged ≥65 years yearly visit the emergency department due to falling, resulting in a mean cost of €9370 per fall, increasing to €14,600 per fall in patients aged ≥80 years \[[@CR11]\].

Most guidelines on dizziness tend to advocate a diagnosis-oriented approach regardless of the age of the patient \[[@CR12], [@CR13]\]. The diagnosis-oriented approach starts with a search for the cause of dizziness, and treatment follows once an illness is diagnosed. For several reasons, this diagnosis-oriented approach may be insufficient in older patients presenting with dizziness. Firstly, in 40 % of older patients with dizziness GPs are not able to identify an underlying cause \[[@CR1]\]. Secondly, a number of common underlying causes of dizziness cannot be treated (such as polyneuropathy) or hardly treated (such as orthostatic hypotension). Finally, clinicians may identify causes of dizziness for which treatment is available but not desirable (such as the Epley manoeuvre for benign paroxysmal position vertigo in patients with severe cervical arthrosis). Croft et al. recently stated that many illnesses cannot usefully be labelled from a disease-diagnosis perspective \[[@CR14]\]. They argued that in such cases, a prognostic model can provide an alternative framework for clinical practice that extends beyond disease and diagnosis, and incorporates a wide range of information to predict future patient outcomes and to guide decisions to improve them \[[@CR14]\].

Tinetti et al. suggested that dizziness in the aged may constitute a multifactorial geriatric syndrome \[[@CR4], [@CR15]\]. Geriatric syndromes, such as delirium, falls, incontinence, and frailty, are highly prevalent, multifactorial, and associated with substantial morbidity and poor outcomes \[[@CR16]\]. Research on contributory factors for dizziness in older people has strengthened the idea of dizziness in the aged as being a geriatric syndrome \[[@CR17]--[@CR21]\]. Several researchers presume that a multifactorial intervention, targeting contributory factors of the geriatric dizziness syndrome, might reduce dizziness and dizziness-related impairment \[[@CR4], [@CR8], [@CR15], [@CR17], [@CR18], [@CR21]\]. To date, the effectiveness of such a multifactorial approach has not been investigated. In this study, aged patients with dizziness will be offered a multi-component intervention in a so-called prognosis-oriented approach. This prognosis-oriented approach focuses on the identification of modifiable risk factors for an unfavourable course of dizziness, after which treatment will be offered that addresses the modifiable risk factors \[[@CR22]\].

The aim of this study is to evaluate the effectiveness of a prognosis-oriented approach in older people with dizziness in primary care. We will perform an intervention study to investigate the effectiveness of a risk factor-guided intervention for treating dizziness in older patients. This risk factor-guided intervention consists of the following interventions: (1) medication adjustment in case of ≥3 prescribed fall-risk-increasing drugs (FRIDs), (2) stepped care in case of anxiety and/or depression, and (3) exercise therapy in case of impaired functional mobility. Alongside this intervention study we will validate a previously developed seven-item risk score for chronic dizziness with persistent impairment in older people \[[@CR19]\].

Methods/Design {#Sec2}
==============

The study has a three-arm design to perform both an intervention study and a validation study with a 1-year prospective follow-up period (Fig. [1](#Fig1){ref-type="fig"}). The intervention study is a cluster randomized controlled trial, designed to investigate the effectiveness of a risk factor-guided multi-component intervention for treating dizziness in older patients. The aim of the validation study is to validate a previously developed risk score for chronic dizziness with persistent impairment in older people in primary care \[[@CR19]\]. Patients will be assigned to one of three study groups: the intervention group (Fig. [1](#Fig1){ref-type="fig"}, group A), the observational cohort (Fig. [1](#Fig1){ref-type="fig"}, group B), and the control group (Fig. [1](#Fig1){ref-type="fig"}, group C). In the intervention study, the intervention group and the control group will be compared. The validation study comprises the observational cohort and the control group.Fig. 1Flow chart of the study. \* High risk or low risk of chronic dizziness with persistent impairment. *DHI* Dizziness Handicap Inventory, *MHNP* mental health nurse practitioner, *GP* general practitioner, *pharm* pharmacologist, *physio* physiotherapist

The study was approved by the Medical Ethics Review Committee of VU University Medical Center (approval number: NL49604.029.14), and will be conducted according to the principles of the Declaration of Helsinki (version 2013) and the Dutch Medical Research Involving Human Subjects Act (WMO). For this paper, we followed the Consolidated Standards of Reporting Trials (CONSORT) statement with extension to cluster randomised trials \[[@CR23]\].

Sample and setting {#Sec3}
------------------

Patients will be recruited from 46 general practices in an urban area in the Netherlands. Patients of 65 years and older are eligible to participate in the study if they have consulted their general practitioner (GP) for dizziness in the preceding 3 months, and if they are significantly impaired by their dizziness. We define dizziness as recurrent dizziness for at least 1 month, including a giddy or rotational sensation, loss of balance, faint feeling, light-headedness, instability, and/or tendency to fall \[[@CR8]\]. The Dizziness Handicap Inventory (DHI) will be used to assess impairment due to dizziness. A DHI score of ≥30 corresponds with significant impairment due to dizziness \[[@CR24]\]. Exclusion criteria are severe cognitive impairment, terminal illness, severe psychiatric problems, and the inability to speak, read and write Dutch.

Randomisation {#Sec4}
-------------

In the intervention study, cluster randomisation at practice level will be conducted to avoid contamination. General practices will be randomised by a researcher who is blinded to their identity (concealment of allocation) before the inclusion of patients begins. Practices will be stratified by list size into practices with up to 400, 400 to 800, and over 800 patients of 65 years and older. For each stratum, block randomisation with varying block size will be used to create similar distributions in the study arms. The investigator is also blinded to the size of each block.

Sample size calculation {#Sec5}
-----------------------

We intend to include a total of 300 subjects. The sample size calculation for our intervention study is based on the difference in change in 1-year DHI score between the intervention group and the control group. We consider a DHI score difference of 11 or more to be clinically relevant \[[@CR25]\]. With an α of 0.05, a β of 0.20, an intraclass correlation coefficient of 0.05, and the assumption of a loss to follow-up of 20 %, a sample of 100 patients in both the intervention and control group is needed.

To calculate the sample size of the validation study, a commonly used rule of thumb is followed that at least 10 events per variable are available for developing diagnostic and prognostic models. The previously developed risk score that will be validated consists of seven predictors and estimates the functional prognosis of dizziness at 6 months. With the assumption that 60 % of the patients with a DHI score ≥30 at baseline will have a DHI score of ≥30 after 6 months of follow-up \[[@CR26]\], a sample of 100 patients in both the observational cohort and the control group will enable validation of the previously developed risk score.

Recruitment {#Sec6}
-----------

Patients will be recruited by the GPs via two routes. Firstly, GPs will invite patients to participate in the study during consultation hours. Secondly, every 3 months older patients with dizziness will be identified by searching the electronic medical records (EMRs) in all participating general practices. The search in the EMRs will be executed by searching for International Classification of Primary Care (ICPC) codes N17 (dizziness) and H82 (vertiginous syndromes), and free text words dizz\*, vertig\*, and the Dutch equivalent for 'dizz'.

All patients will receive an invitation letter from their GP including study information and the DHI to assess impairment due to dizziness. Patients interested in participating will be asked to send back a completed DHI to the researcher. The researcher will contact all patients with a DHI score of ≥30 to arrange an appointment for baseline assessment at the patient's home. Before the start of baseline assessment, written informed consent will be obtained from each participant.

Assignment to study groups {#Sec7}
--------------------------

Assignment to one of the three study groups (Fig. [1](#Fig1){ref-type="fig"}) is based on the risk of chronic dizziness with persistent impairment, which will be assessed during baseline assessment at the patient's home. An older patient with dizziness will be labelled as having a high risk for chronic dizziness with persistent impairment if they have a DHI score of ≥30 at baseline and the presence of one, two, or three of the following risk factors: (1) three or more prescribed FRIDs, (2) anxiety disorder and/or depression, and (3) impaired functional mobility.

Patients with a high risk of chronic dizziness will participate in the intervention group or control group, depending on whether their general practice is an intervention practice or control practice respectively. Older patients with dizziness with significant impairment, but at low risk of chronic dizziness with persistent impairment, will be allocated to the observational cohort.

In sum, the intervention study consists of a control group with patients with dizziness-related impairment and a high risk of chronic dizziness that will receive usual care (Fig. [1](#Fig1){ref-type="fig"}, group C), and an intervention group that receives usual care plus one, two, or three interventions (Fig. [1](#Fig1){ref-type="fig"}, group A). In sum, the intervention study consists of impaired dizzy patients with a 'high risk' that will receive usual care in the control group (Fig. [1](#Fig1){ref-type="fig"}, group C) and usual care plus 1, 2, or 3 interventions in the intervention group (Fig. [1](#Fig1){ref-type="fig"}, group C).

Interventions {#Sec8}
-------------

All patients of the intervention group (n = 100) will receive usual care plus one, two, or three risk factor-guided interventions. The offered interventions are: (1) medication adjustment in case of three or more prescribed FRIDs; (2) stepped care in case of anxiety disorder and/or depression; and (3) exercise therapy in case of impaired functional mobility. Patients eligible for more than one intervention will start the applicable interventions at the same time.

### Medication adjustment in case of three or more fall-risk-increasing drugs {#Sec9}

This intervention will be similar to the 'FRID withdrawal' study by Van der Velde et al. \[[@CR27], [@CR28]\]. The list of FRIDs includes psychotropic drugs (sedatives, antidepressants, and neuroleptics), cardiovascular drugs (antihypertensives, nitrates, anti-arrhythmics, nicotinic acid, and β-adrenoceptor blocker eye drops), and other drugs (analgesics, anti-vertiginous drugs, hypoglycaemics, and urinary antispasmodics) \[[@CR27]\]. Once a month, a pharmacist and an independent GP will have a meeting to review the FRID use of all patients eligible for the intervention 'medication adjustment' that have been included in the preceding month. In every individual patient, all potential FRIDs will be considered for withdrawal. The use of FRIDs will be stopped if no health risks are involved, or reduced in dose when stopping is not an option. The FRID medication advice will be handed to the patient's GP, who will be asked to invite the patient on his or her consultation hour to discuss the FRID medication advice. FRID medication adjustment will only take place if both the GP and the patient agree.

### Stepped care for anxiety disorder and/or depression {#Sec10}

Older patients with dizziness in the intervention group with the risk factor 'anxiety disorder and/or depression' (defined as the presence of generalised anxiety disorder (GAD), panic disorder (PD) or major depressive disorder (MDD)), will be offered a stepped care program, based on the Trimbos Multidisciplinary Guideline Anxiety Disorders \[[@CR29]\] and the Trimbos Multidisciplinary Guideline Depression \[[@CR30]\]. The presence of GAD, PD, and/or MDD will be assessed by the Generalised Anxiety Disorder-7 (GAD-7) \[[@CR31]\], Patient Health Questionnaire Panic Module (PHQ-PD) \[[@CR32]\], and Patient Health Questionnaire-9 (PHQ-9) \[[@CR33], [@CR34]\], respectively.

The offered stepped-care program involves four subsequent evidence-based treatment steps for anxiety disorder and depression in primary care, lasting 6 weeks each. A mental health nurse-practitioner (MHNP) working in the patient's own general practice will guide the patient through the steps of the program. All participating MHNPs will receive a training before the start of the intervention. If needed, the GP will be available for the MHNP to discuss a patient. The patient flow through the stepped care program depends on the patient's symptom level, as measured with the GAD-7, PHQ-PD, and PHQ-9 at the end of every step. Patients who still have elevated anxiety or depression symptom scores (a GAD-7 score ≥10, a PHQ-9 score ≥10, or a positive PHQ-PD score) after concluding a step will be invited to participate in the next step. The steps are listed below:Step 1(watchful waiting): The first 6 weeks consists of watchful waiting. At the start of step one the MHNP will invite the patient for an introductory consultation. The patient will get acquainted with the MHNP and the MHNP will inform the patient about the stepped-care program. No therapy will be offered during step one.Step 2(guided self-help treatment): During this step the patient will start with a guided self-help course of 6 weeks. The course is based on Lewinsohn's 'Coping with Depression' course \[[@CR35]\] and modified for patients of 65 years and over who suffer from anxiety disorder and/or depression. The course includes of six modules that last a week each. The patient will read about new insights and skills and is challenged to perform exercises. The consecutive modules focus on acknowledgment of being anxious or depressed, relaxation, pleasant activity scheduling, changing of cognitions, and assertiveness. The MHNP will call the patient every 2 weeks.Step 3(problem-solving treatment; PST): PST is a brief cognitive behavioural intervention that focuses on practical skill building, education, and managing anxiety and/or depression symptoms. The goal is to reduce mental health problems by stimulating an active attitude towards everyday problems \[[@CR36]\]. PST will be offered by the MHNP and takes a maximum of six sessions of 30 min at the GP surgery. The stages of problem-solving are explained during the sessions and then applied to problems that are encountered in daily life.Step 4(referral to the GP): The GP will have a consultation with the patient to assess what would be an appropriate next therapy for the patient (for example, starting with antidepressants or referral to a psychologist). The GP will then initiate the treatment.

### Exercise therapy in case of impaired functional mobility {#Sec11}

Older patients with dizziness-related impairment in the intervention group with the risk factor 'impaired functional mobility' (defined as a Timed Up-and-Go score of 20 s or more \[[@CR37]\]), will receive standardized exercise therapy by a physiotherapist of the patient's choice. Physical exercise therapy has a positive effect on mobility and physical functioning in mobility limited and/or physically disabled older patients \[[@CR38]\]. We choose for an individual intervention because the effect of individual interventions seems to be somewhat larger than the effect of group interventions \[[@CR38]\]. The aim of exercise therapy is to improve resistance and balance because this might improve strength and balance, which are often implicated as a cause of mobility impairment \[[@CR39]\]. The intervention implies training of one hour twice a week for 8 weeks. Every training session starts with exercises on sitting balance, static standing balance, and trunk stability. The program then continues with seated leg press, cable lat pulldown, cycling, and concludes with walking on the treadmill. The physiotherapists will receive study information and a treatment protocol that is designed together with a senior physiotherapist specialised in exercise programs. The treatment protocol prescribes what exercises should be carried out every week and includes pictures of the specific exercises. The treatment protocol is designed to give individualised care: the intensity of the exercise therapy will be adjusted according to the patients' physical condition that will be tested during the intake.

Usual care {#Sec12}
----------

Patients in the control group and the observational cohort will have unrestricted access to usual care: no treatment will be denied to any participants nor will it be postponed. The GPs of control practices will not be informed about the intervention and will not receive any training. Instead, they will be asked to provide care as recommended in the guideline 'Dizziness' of the Dutch College of General Practitioners \[[@CR13]\].

Primary outcome measure {#Sec13}
-----------------------

All primary and secondary outcome measures are summed up in Table [1](#Tab1){ref-type="table"}. The intervention group and control group will be followed up on at 3, 6, and 12 months; the observational cohort will be followed up on at 6 and 12 months.Table 1Overview of measurements and instrumentsValidation studyIntervention studybaseline6 months12 monthsbaseline3 months6 months12 monthsBaseline assessmentxxDizziness Handicap (DHI)xxxxxxxQoL (EQ-5D-5L)xxxxxxDepression (PHQ-9)xxxxxxxAnxiety (GAD-7)xxxxxxxHealth care utilisation (EMR)xxPanic disorder (PHQ-PD)xxxxxxxFRID countxxxxDizziness and fall frequency (calendar)\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-- weekly \-\-\-\-\-\-\-\-\-\-\-\-\-\--*DHI* dizziness handicap inventory, *EMR* electronic medical records, *FRID* Fall-risk-increasing drug, *GAD*-*7* Generalised Anxiety Disorder-7, *PHQ*-*9* Patient Health Questionnaire-9, *QoL* Quality of Life, *PHQ*-*PD* Patient Health Questionnaire Panic Module

The primary clinical outcome is dizziness-related impairment, which will be assessed using the DHI \[[@CR24]\]. The DHI is a widely used self-report questionnaire, designed to quantify the impact of dizziness on everyday life, with scores ranging from 0 to 100. A DHI score of ≥30 correlates with current significant impairment because of dizziness \[[@CR24]\]. In the intervention study, the primary outcome is the difference in change in 1-year DHI score between patients in the intervention group and patients in the control group. For the validation study, we will dichotomise all DHI scores (\<30 or ≥30).

Secondary outcome measures {#Sec14}
--------------------------

Secondary outcome measures that will be measured in both the intervention study and the validation study are quality of life, presence of anxiety disorder and/or depression, and healthcare utilisation. Furthermore, in the intervention study dizziness frequency, fall frequency, and difference in FRID count will also be measured.

Quality of life, will be measured with the Euro Quality of Life-5-dimension, 5-level (EQ-5D-5L) \[[@CR40]\]. The EQ-5D-5L is a questionnaire that assesses health in five dimensions (mobility, self-care, usual activities, pain and/or discomfort, and anxiety and/or depression).

Presence of anxiety disorder and/or depression will be measured with GAD-7, PHQ-PD, and PHQ-9 \[[@CR31]--[@CR34]\].

Healthcare utilization: after informed consent, we will extract data from the general practitioners' EMRs of all participating patients to assess the number of consultations, prescriptions, referrals, hospital admissions, and nursing home admissions.

Dizziness frequency and fall frequency, defined as the number of episodes of dizziness and falls per day, week, month, and year, will be assessed using a calendar filled in by the patient during a 12-month period. The calendar is similar to a fall calendar used in an earlier study \[[@CR41]\], and is designed to monitor dizziness frequency additionally to fall frequency.

Difference in FRID count, defined as the difference in number of prescribed FRIDs between baseline and at 12 months follow-up, will also be measured.

Statistical analysis {#Sec15}
--------------------

### Intervention study {#Sec16}

We will use descriptive statistics to describe the study population. Dropout and loss to follow-up will be described. The primary analysis will be an intention-to-treat analysis. We will also perform a per-protocol analysis. Univariate and multivariate analyses will be used to compare the outcomes of the intervention group and control group. Regardless of whether intervention patients received one, two, or three interventions, the overall change in 1-year DHI-score in the intervention group will be compared to the change in 1-year DHI-score in the control group. We will use a repeated-measures mixed-effect model to assess differences in the overall change in 1-year DHI score in the intervention group and control group, adjusted for potential confounders. Furthermore subgroup analysis will be performed for three groups separately that received one of three interventions. The overall change in 1-year DHI score in these three subgroups will be compared to the overall change in 1-year DHI score in the control group.

### Validation study {#Sec17}

Descriptive statistics will be used to describe the study population. Dropout and loss to follow-up will be described. The validity of our seven-item risk score in this study group will be quantified by assessing the reliability, discrimination, and calibration of the model \[[@CR42]\]. The reliability of the model will be quantified with the Hosmer-Lemeshow goodness-of-fit statistic. We will assess the calibration of the model by plotting the predicted probabilities against the observed frequencies of persistent dizziness-related impairment. We will assess the discriminative ability of the model, that is, its ability to distinguish patients with dizziness and persistent dizziness-related impairment from patients with dizziness but without persistent dizziness-related impairment, by calculating the receiver operating characteristic curve (AUC). An AUC of 0.5 indicates no discrimination above chance, whereas an AUC of 1.0 indicates perfect discrimination. We will bootstrap to adjust for over-optimism in model performance.

Discussion {#Sec18}
==========

This study is expected to add evidence on the effectiveness of a prognosis-oriented approach for dizziness in older people in primary care. The risk factor-guided intervention of this prognosis-oriented approach will provide the GP with more tools for treatment, even if diagnosis is not (yet) available. An important aim of the intervention study is to reduce dizziness-related impairment in older patients. The intervention may also lead to a decrease in healthcare costs by a reduction of healthcare utilisation in secondary and tertiary care. Furthermore, the availability of a new effective intervention for older patients with dizziness may stimulate GPs to reduce unnecessary drug prescribing \[[@CR43]\]. Alongside the intervention study we will validate a previously developed seven-item risk score for chronic dizziness with persistent impairment \[[@CR19]\]. Once validated, this risk score will enable GPs to identify patients at high risk for chronic dizziness with persistent impairment.

A strength of this study is that it is, to date, the first study that will investigate the effectiveness of a prognosis-oriented approach on reducing dizziness-related impairment in a large group of older people in primary care. Several researchers have suggested that a multi-component intervention targeting contributory factors of the geriatric syndrome dizziness may reduce dizziness and dizziness impairment \[[@CR4], [@CR8], [@CR15], [@CR17], [@CR18], [@CR21]\]. Yet this study goes even further by applying a prognosis-oriented approach instead of a general multifactorial approach. The prognosis-oriented approach focuses on modifiable risk factors for an unfavourable course of dizziness, whereas the multifactorial approach focuses on random contributory factors for the geriatric syndrome dizziness. Also, Croft et al. recently argued that patient prognosis can provide the framework for modern clinical practice for more effective and efficient care \[[@CR14]\]. Another strength of this study is the pragmatic design, enabling evaluation of the outcomes in real-life routine practice conditions. The pragmatic design increases the generalizability of our outcomes and increases the possibility of implementing the prognosis-oriented approach in daily clinical practice.

Due to the nature of the interventions, it will not be possible to blind patients and caregivers to the interventions. To avoid contamination within practices, we have chosen a cluster randomised design: GPs and MHNPs in control practices will not receive training, as opposed to GPs and MHNPs in intervention practices who will. Offering several interventions to a single patient might make measurement of the effects of the separate interventions impossible. However, based on earlier research we expect that the majority of patients (60 %) will be eligible for only one intervention (additional analysis, \[[@CR26]\]). This will also enable us to analyse the effects of the individual interventions.

In summary, the overall aim of this study is to demonstrate that a prognosis-oriented approach is more effective than usual care when treating dizziness in older patients in primary care. We will do this by measuring the effectiveness of a multi-component intervention for dizziness. Alongside the intervention study we will validate a previously developed seven-item risk score for chronic dizziness with persistent impairment.

Trial status {#Sec19}
============

The collection of data started in January 2015. The first study results are expected in 2016.
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